Journal
EXPERT REVIEW OF VACCINES
Volume 17, Issue 6, Pages 479-493Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2018.1413354
Keywords
Herd effect; invasive pneumococcal disease; non-vaccine serotypes; pneumococcal conjugate vaccine; serotype replacement; surveillance; vaccine serotypes
Categories
Funding
- GlaxoSmithKline Biologicals SA
Ask authors/readers for more resources
Introduction: Pneumococcal conjugate vaccine (PCV) impact studies have reported substantial reductions in the incidence of invasive pneumococcal disease (IPD) after implementation of childhood PCV programs. Heterogeneity in surveillance systems, local epidemiology and PCV programs hampers comparisons between studies. We aimed to better understand the impact of childhood PCV programs on overall IPD and serotype distribution.Areas covered: We analyzed the impact of PCV programs on the incidence of overall IPD, and the distribution of vaccine serotypes (VT) and non-vaccine serotypes (NVT) in children <5years and adults 65years old. We retrieved datasets from observational post-marketing studies and surveillance reports from countries with high-quality surveillance data available for at least 2years before PCV program initiation and 3years after higher-valent PCV implementation. We harmonized pre- and post-PCV analysis periods and assessment methods.Expert commentary: After introduction of pediatric PCV programs, the residual overall IPD burden in children was low and in a narrow range across countries with high vaccination coverage, irrespective of differences in PCV programs and pneumococcal epidemiology. Effects on overall IPD were more variable in the elderly. Whereas IPD was mainly due to VTs before PCV introduction, NVTs are the major contributor today in children and adults.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available